Australia's most trusted
source of pharma news
Friday, 13 March 2026
Posted 13 March 2026 PM
The disappearing act of a first-in-class PBS drug listed just 14 months ago was the top story this week.
Onpattro, was reimbursed from August 2024 - becoming the first RNA interfering molecule to be listed, the first subsidised treatment for hereditary transthyretin-mediated amyloidosis, and the first of Alnylam's drugs to hit the Australian market.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.